PGNY, US74340E1038

Progyny stock: Truist raises price target to 42 US dollars

Published on 11/19/2026 at 04:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Truist reiterated its Buy rating after lifting its target from 36 US dollars. Progyny stock remains in focus as analysts reassess its outlook.

Analyst target points higher

  • Truist reiterated its Buy rating on Progyny after a stronger third quarter and lifted its price objective.
  • Progyny's latest quarter included record revenue, higher net income and a raised full-year outlook.
PGNY, US74340E1038, Illustration mit AI erstellt.

Truist Financial reiterated its Buy rating on Progyny and raised its price target from 36 to 42 US dollars, according to a MarketBeat report published Tuesday, November 17. The broker retained its Buy assessment as investors weighed Progyny's recent earnings and higher full-year outlook.

Target raised after strong quarter

Progyny reported third-quarter revenue of 341.25 million US dollars, up 8.9 percent from a year earlier. Net income reached 26.25 million US dollars, compared with 13.86 million US dollars in the prior-year quarter, while adjusted earnings per diluted share were 0.52 US dollars.

The company raised its full-year 2026 revenue outlook to 1.365 billion to 1.385 billion US dollars and forecast adjusted EBITDA of 235 million to 240 million US dollars. Management also said the latest selling season produced 1.3 million new covered lives and more than 85 new clients, with most expected to begin in 2027.

Business model and market position

Progyny provides fertility and family-building benefits to employers and their employees. Its services support fertility treatment, specialist access, medication benefits, egg freezing, adoption and surrogacy, depending on the selected plan. The company operates in the employer-sponsored healthcare and family-building benefits market.

Progyny at a glance

  • Company: Progyny, Inc.
  • ISIN: US74340E1038
  • Ticker: PGNY
  • Home exchange: Nasdaq
  • Sector: Healthcare

The company trades in the US market, where investors also track the S&P 500.

More news and analyses on Progyny stock are available here.

Disclaimer...
en | US74340E1038 | PGNY | boerse | 70533474 | bgmi